Forward Pharma’s golden ticket is fading
US drug company Biogen’s cash cow, sclerosis drug Tecfidera, is taking a hit on new scripts, says a senior portfolio manager. It could affect Forward Pharma, which believes it holds the rights to the drug.
BY STEFAN SINGH KAILAY & MARTIN HAVTORN PETERSEN
The massive expectations for Biogen’s multiple sclerosis drug Tecfidera are beginning to wane, says Claus Henrik Johansen, senior portfolio manager in Danske Capital, in the wake of an investor conference held by Cowen in New York.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Forward Pharma wins EU patent
For abonnenter
Forward Pharma kicks off US patent war
For abonnenter
”Forward Pharma has been overlooked”
For abonnenter
